Increased peripheral levels of inflammatory biomarkers and oxidative stress biomarkers seen in people with severe mental illness or T2DM
THURSDAY, Aug. 11, 2022 (HealthDay News) — Individuals with severe mental illness or type 2 diabetes mellitus (T2DM) have increased levels of peripheral immune-inflammatory biomarkers, which may contribute to neurocognitive and social deficits, according to a study recently published in the Frontiers of Neurology.
Marta Garés-Caballer, M.D., from the University of Valencia in Spain, and colleagues conducted a prospective one-year follow-up cohort study involving 165 participants at baseline (30 with schizophrenia, 42 with bipolar disorder, 35 with major depressive disorder, 30 with T2DM, and 28 healthy controls) and 125 participants at one-year follow-up. Executive domain, global social functioning score, and peripheral blood immune-inflammatory and oxidative stress biomarkers were determined.
The researchers found increased peripheral levels of inflammatory markers, such as interleukin-10 and tumor necrosis factor-α, and oxidative stress biomarkers, such as reactive oxygen species (ROS) and mitochondrial ROS, were seen among participants with severe mental illness and T2DM. For participants with severe mental illness, the different combinations of the exposed biomarkers anticipated 46.0 to 57.3 percent of the total executive domain and 23.8 to 35.7 percent of the global social functioning score.
“Our current results elucidated the predictive power of peripheral biomarkers for immune-inflammatory activity in relation to social and executive functioning in patients with [severe mental illness] and T2DM,” the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Estimated Glucose Disposal Rate Inversely Linked to Benign Prostatic Hyperplasia
Small Change in Hours Benefits Emergency Physicians Working Night Shifts
Safety Intervention Reduces Incidence of Postoperative Endophthalmitis
Exposure to Air Pollutants Linked to Increased RA Disease Activity
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Consensus Statements Developed for Rheumatoid Arthritis-Linked Interstitial Lung Disease
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis